DIAGNOSIS AND TREATMENT: INTERPRETATION OF RESULTS OF BLOOD SCREENING STUDIES FOR DETECTION OF PHENYLKETONURIA

PEDIATRICS ◽  
1966 ◽  
Vol 37 (1) ◽  
pp. 102-106
Author(s):  
Helen K. Berry ◽  
Betty S. Sutherland ◽  
Barbara Umbarger

THE American Academy of Pediatrics Committee on Fetus and Newborn recently recommended that a blood test for elevated concentration of phenylalanine be performed for all newborn infants prior to discharge. As results become available from wide application of blood screening tests, a number of questions have arisen regarding the interpretation of positive findings of elevated blood phenylalanine levels. Some reports suggest that diagnosis of phenylketonuria is determined by elevation of blood phenylalanine. The conclusion may be erroneously drawn that such a finding in an infant calls for immediate treatment with a low-phenylalanine diet. There are instances in which children were fed a phenylalanine restricted diet for periods up to 18 months and subsequently were proven not to have phenylketonuria. In another study plasma phenylalanine levels up to 40 mg/100 ml in a premature infant, accompanied by elevation of tyrosine, were shown not to result from phenylketonuria. Some investigators urge that tests for urinary metabolites characteristic of phenylketonuria be a necessary part of the diagnosis, while others consider urine testing of little value. The cause for the mental defect in phenylketonuria has not been established with certainty. No satisfactory explanations have been proposed to account for the rare individuals with normal intelligence and biochemical phenylketonuria. It is not known whether elevation of phenylalanine from disorders other than phenylketonuria might result in mental impairment. We have carried on a broad-scale urinescreening program since 1958 and a bloodscreening program since 1961. At the same time we have accumulated 70 patient years of experience in treatment of phenylketonuria.

PEDIATRICS ◽  
1965 ◽  
Vol 35 (6) ◽  
pp. 1021-1021
Author(s):  
ROBERT A. MACCREADY

The report of the Committee on Fetus and Newborn of the American Academy of Pediatrics on "Screening of Newborn Infants for Metabolic Disease," appearing in Pediatrics (35:499) contains the statmeent, "A blood test for elevated concentration of phenylalanine performed no sooner than 24 hours after onset of milk feeding and prior to discharge from the hospital is recommended for all newborn infants." It is important to add that this test should be performed on blood drawn as late as possible before discharge of the newborn baby from the hospital.


2011 ◽  
Vol 106 (2) ◽  
pp. 175-182 ◽  
Author(s):  
Anita MacDonald ◽  
Kirsten Ahring ◽  
Katharina Dokoupil ◽  
Hulya Gokmen-Ozel ◽  
Anna Maria Lammardo ◽  
...  

The usual treatment for phenylketonuria (PKU) is a phenylalanine-restricted diet. Following this diet is challenging, and long-term adherence (and hence metabolic control) is commonly poor. Patients with PKU (usually, but not exclusively, with a relatively mild form of the disorder) who are responsive to treatment with pharmacological doses of tetrahydrobiopterin (BH4) have either lower concentrations of blood phenylalanine or improved dietary phenylalanine tolerance. The availability of a registered formulation of BH4 (sapropterin dihydrochloride, Kuvan®) has raised many practical issues and new questions in the dietary management of these patients. Initially, patients and carers must understand clearly the likely benefits (and limitations) of sapropterin therapy. A minority of patients who respond to sapropterin are able to discontinue the phenylalanine-restricted diet completely, while others are able to relax the diet to some extent. Care is required when altering the phenylalanine-restricted diet, as this may have unintended nutritional consequences and must be undertaken with caution. New clinical protocols are required for managing any dietary change while maintaining control of blood phenylalanine, ensuring adequate nutrition and preventing nutritional deficiencies, overweight or obesity. An accurate initial evaluation of pre-sapropterin phenylalanine tolerance is essential, and the desired outcome from treatment with sapropterin (e.g. reduction in blood phenylalanine or relaxation in diet) must also be understood by the patient and carers from the outset. Continuing education and support will be required thereafter, with further adjustment of diet and sapropterin dosage as a young patient grows.


2002 ◽  
Vol 283 (6) ◽  
pp. E1249-E1256 ◽  
Author(s):  
Glenda Courtney-Martin ◽  
Rachelle Bross ◽  
Mahroukh Raffi ◽  
Joe T. R. Clarke ◽  
Ronald O. Ball ◽  
...  

Dietary restriction of phenylalanine is the main treatment for phenylketonuria (PKU), and current estimates of requirements are based on plasma phenylalanine concentration and growth. The present study aimed to determine more precisely the phenylalanine requirements in patients with the disease by use of indicator amino acid oxidation, withl-[1-13C]lysine as the indicator. Breath13CO2 production (F13 co 2) was used as the end point. Finger-prick blood samples were also collected for measurement of phenylalanine to relate phenylalanine intake to blood phenylalanine levels. The mean phenylalanine requirement, estimated using a two-phase linear regression crossover analysis, was 14 mg · kg−1 · day−1, and the safe population intake (upper 95% confidence interval of the mean) was found to be 19.5 mg · kg−1 · day−1. A balance between phenylalanine intake and the difference between fed and fasted blood phenylalanine concentration was observed at an intake of 20 mg · kg−1 · day−1. The similarity between these two values (19.5 and 20 mg · kg−1 · day−1) suggests that the maximal phenylalanine intake for children with PKU should be no higher than 20 mg · kg−1 · day−1.


PEDIATRICS ◽  
1996 ◽  
Vol 98 (3) ◽  
pp. 473-501 ◽  

These newborn screening fact sheets were developed by the Committee on Genetics of the American Academy of Pediatrics (AAP) with considerable assistance and consultation from many individuals. It is hoped that the information contained in these fact sheets will assist the pediatrician in understanding the individual tests, their characteristics, and their strengths and weaknesses. Newborn screening is an individual function of each state; therefore, screening programs are not uniform throughout the United States (Table). Because the test results can affect children and parents in a variety of ways, there are special concerns about how states make decisions to adopt new tests and how they evaluate their current screening panels. Currently, many states are examining their practices. The informatiion in the fact sheets was not designed to advocate specific newborn screening tests but to assist pediatricians in evaluating policies and procedures and in developing appropriate positions based on the needs of their patients and their geographic regions.


2020 ◽  
pp. 75-81
Author(s):  
Paul Ishimine

Fever is the most common complaint of children who present to the emergency department. Approximately 12% of febrile neonates (aged 0–28 days) and young infants (aged 29—56 days) have serious bacterial infections (bacteremia, meningitis, urinary tract infections, pneumonia, bacterial gastroenteritis, and osteomyelitis). The evaluation and management of the febrile neonate and febrile young infant can be confusing. All febrile neonates require diagnostic testing, treatment with antibiotics, and hospital admission. The workup of the febrile young infant is more controversial. These patients should undergo blood and urine testing, but the need for lumbar puncture is controversial, as is the need for empiric antibiotic treatment. The disposition of these patients will depend on the results of these screening tests.


1972 ◽  
Vol 61 (3) ◽  
pp. 279-284 ◽  
Author(s):  
JULIAN L. BERMAN ◽  
ROSITA S. PILDES ◽  
CHARLES M. BLUMENFELD

2005 ◽  
Vol 133 (3) ◽  
pp. 485-491 ◽  
Author(s):  
C. G. CARVALHEIRO ◽  
M. M. MUSSI-PINHATA ◽  
A. Y. YAMAMOTO ◽  
C. B. S. DE SOUZA ◽  
L. M. Z. MACIEL

Congenital toxoplasmosis is rarely identified by routine clinical examination. The aim of this study was to estimate the incidence of the disease in the region of Ribeirão Preto, south-eastern Brazil. A definitive diagnosis was made on the basis of the persistence of anti-Toxoplasma IgG antibodies beyond 1 year of age. Blood samples obtained from 15162 neonates and adsorbed onto filter paper were tested for anti-Toxoplasma IgM antibodies. Fifteen samples gave positive results. A definitive diagnosis was confirmed in five of the 13 infants (38·5%) who completed follow-up. These five infants presented with serum IgM and/or IgA antibodies, and clinical abnormalities. Disease incidence was estimated to be 3·3/10000 (95% CI 1·0–7·7), indicating the need for preventive measures. Neonatal screening is feasible, but screening tests with a better performance are required; positive screening results must be carefully confirmed.


2021 ◽  
Vol 32 (3) ◽  
pp. 181-190
Author(s):  
Dong Hee Seo ◽  
Hyoung Ju Yoon ◽  
Jae Chan Ahn ◽  
Yoo-Sung Hwang

Blood ◽  
1970 ◽  
Vol 35 (4) ◽  
pp. 462-475 ◽  
Author(s):  
ROBERT C. HARTMANN ◽  
DAVID E. JENKINS ◽  
ANITA B. ARNOLD

Abstract The diagnostic specificity of the various modifications of the sucrose hemolysis test for PNH was examined in detail. In whole blood screening tests the greatest specificity was achieved using citrated or oxalated blood and room temperature incubation (23°). Defibrinated whole blood should not be used since "false positive" hemolysis may occur in blood disorders other than PNH. Mechanisms were suggested for this phenomenon. The validity of the confirmatory sucrose hemolysis test employing normal serum was further reported. Because of the clear, colorless character of serum-sucrose mixtures, an insignificant degree of hemolysis (i.e., less than 5%) is more readily visible than in other PNH hemolytic tests employing undiluted serum. Definitive instructions and criteria for interpretation were given for both the whole blood screening test and the confirmatory sucrose hemolysis test.


Sign in / Sign up

Export Citation Format

Share Document